Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jasen Chi (NPI 1437141322)

Field	Value
Entity Type	Individual
Organization	Jasen Chi
Address	6 Shackleford Dr
City	Little Rock
State	AR
ZIP	72211
Taxonomy	Rheumatology Physician
NPI Enumerated	August 17, 2005

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider is effectively single-payer with respect to public programs: lifetime Medicare revenue is $1.5M while there is none recorded for Medicaid, so Medicaid does not contribute to this provider’s public-payor volume or revenue mix. Analysts should treat Medicare as the primary and only public source for assessing government-covered care and reimbursement patterns for this NPI.

Revenue concentration is notable: the precomputed top 3 Medicare codes by revenue account for 43.1% of the provider’s total Medicare revenue, indicating a substantial portion of earnings are driven by a small set of high-revenue drug administration codes and associated services. This concentration suggests that changes in utilization or reimbursement for those specific codes could materially impact the provider’s Medicare revenue.

The top single revenue driver is J0129 (abatacept) with $324.7K revenue representing 22.5% of Medicare revenue; this, together with high revenue shares from Q5104 and J3262, indicates the practice has a biologic infusion/administration emphasis consistent with rheumatology care focused on parenteral disease-modifying therapies. The presence of multiple high-revenue J- and Q-codes points to an in-office infusion service line rather than a purely clinic visit–based practice.

Competitive standing on key biologic codes is mixed. The provider ranks at the 58th percentile nationally on J0129 (typical volume), but ranks at the 90th percentile on Q5104 (infliximab biosimilar) which places them among higher-volume national suppliers for that drug. Conversely, on J9312 (rituximab) the provider ranks at the 1st percentile among a small cohort, indicating unusually low relative volume for that code compared to national peers. These rank/percentile spread signals selective emphasis across different biologics rather than uniformly high or low utilization across all infusion drugs.

Non-drug service lines show concentrated imaging and procedure volumes that are extreme outliers nationally: codes 73620, 73120, 72040, 73565, 72100 and 72170 are all at or near the 100th percentile and labeled as "extreme outlier" or "notably above typical national volume." This suggests the practice either co-locates substantial imaging services (X-rays of extremities, spine, pelvis, knees) or bills heavily for radiographic exams relative to most rheumatologists, which may reflect a broader musculoskeletal diagnostic footprint beyond infusion therapies.

Office evaluation-and-management coding shows above-typical volumes for certain visit codes: 99214 ranks in the 95th percentile (notably above typical) and 99213 ranks in the 98th percentile (notably above typical), while 99204 for new patients is an extreme outlier at the 100th percentile. Together these E/M patterns imply a busy clinic with significant new and established patient throughput, supporting the infusion and diagnostic volumes observed.

Procedure-level infusion and chemotherapy administration codes (96413, 96415, 96365) are present at typical-to-above-typical volumes (ranging from 71st to 94th percentile labels), indicating the provider performs repeated IV medication administrations and extended infusions consistent with specialty infusion services. These add-on and initial infusion codes corroborate the business model centered on in-office parenteral therapy delivery.

The provider has long tenure in the NPI registry, enumerated on 2005-08-17 (~21 years ago). This extended active period supports interpretation of observed patterns as established practice behavior rather than short-term or startup activity, which is relevant when assessing sustainability of the concentrated revenue streams and service lines.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	9,550	$30	$324.7K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	5,160	$30	$154.9K
J3262	Injection, tocilizumab, 1 mg	28,550	$10	$142.7K
J1602	Injection, golimumab, 1 mg, for intravenous use	11,990	$10	$119.9K
J3111	Injection, romosozumab-aqqg, 1 mg	11,970	$10	$95.8K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	21,600	$1	$86.4K
J0897	Injection, denosumab, 1 mg	4,440	$20	$79.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	750	$80	$62.6K
J9312	Injection, rituximab, 10 mg	930	$60	$58.5K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	520	$110	$54.8K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Jasen Chi — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	7	20	8,960	$30	$532.4K
J9312	5	10	6,500	$60	$393.8K
J0717	9	10	66,400	$1	$278.1K
J3262	3	10	28,550	$1	$208.6K
J1602	10	10	15,300	$10	$185.4K
Q5104	3	10	4,050	$30	$124.7K
J3111	4	10	11,240	$10	$116.7K
J0897	55	160	2,580	$20	$89.7K
Q5121	1	10	1,860	$20	$36.8K
96413	47	80	380	$90	$36.6K

Showing 1–10 of 41

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jasen Chi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
White River Health System, Inc.	AR	General Acute Care Hospital	$0	$22.3M
Arcare	AR	Federally Qualified Health Center (FQHC)	$0	$7M
Arcare	AR	Federally Qualified Health Center (FQHC)	$0	$6.6M
Arcare	AR	Federally Qualified Health Center (FQHC)	$0	$5.1M
Arcare	KY	Federally Qualified Health Center (FQHC)	$0	$4.4M
Arcare	AR	Federally Qualified Health Center (FQHC)	$0	$3.9M
Arcare	AR	Federally Qualified Health Center (FQHC)	$0	$3.9M
Arcare	AR	Federally Qualified Health Center (FQHC)	$0	$3.6M
White River Health System, Inc.	AR	Critical Access Hospital	$0	$3.3M
White River Health System, Inc.	AR	Rural Health Clinic/Center	$0	$3.1M

Nearby Providers

Other providers in the same ZIP code as Jasen Chi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Independent Case Management, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$58.7M
Mct, Inc.	AR	Developmental Disabilities Clinic/Center	$0	$30.5M
Pain Treatment Centers Of America, PLLC	AR	Multi-Specialty Clinic/Center	$0	$19.5M
Inspiration Day Treatment, Inc.	AR	Community/Behavioral Health Agency	$0	$11.9M
Bhc Pinnacle Pointe Hospital, Inc.	AR	Adolescent and Children Mental Health Clinic/Center	$0	$10.4M
Mct, Inc.	AR	Speech-Language Pathologist	$0	$9.2M
Turcios & Zarruk Dental, P.A.	AR	Dental Clinic/Center	$0	$5M
James Keane	AR	Procedural Dermatology Physician	$4.9M	$0
Odyssey Healthcare Operating A LP	AR	Home Health Agency	$0	$3.6M
Advanced Spine And Pain Centers, Inc.	AR	Pain Clinic/Center	$0	$3.6M

Jasen Chi — Billing Profile & Reimbursement Data

Sign up for Jasen Chi — Billing Profile & Reimbursement Data policy alerts

Jasen Chi — Billing Profile & Reimbursement Data

Sign up for Jasen Chi — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References